Guérin, 88 patient HCQ early treatment study: 65% faster recovery [p=0.0001] https://c19p.org/guerin
copied to clipboard
Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19
et al., Asian J. Medicine and Health, July 15, 2020, doi:10.9734/ajmah/2020/v18i730224 (preprint 5/31)
Mean clinical recovery time reduced from 26 days (SOC) to 9 days, p<0.0001 (HCQ+AZ) or 13 days, p<0.0001 (AZ). No cardiac toxicity. Small retrospective study of 88 patients with case control analysis with matched patients.
|
risk of death, 61.4% lower, RR 0.39, p = 1.00, treatment 0 of 20 (0.0%), control 1 of 34 (2.9%), NNT 34, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
|
recovery time, 65.0% lower, relative time 0.35, p < 0.001, treatment 20, control 34.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Guérin et al., 5/31/2020, retrospective, France, Europe, peer-reviewed, 8 authors, dosage 600mg days 1-10, 7-10 days, this trial uses multiple treatments in the treatment arm (combined with AZ) - results of individual treatments may vary.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.